ng of the study. The dosage could be increased to a maximum of 120 mg/day based on the investigator’s discretion.¹

The primary data disclosure took place at a major medical conference in December 2006.⁵ The primary objective of the overall study was to demonstrate the non-inferiority of Direct Switch (DS) compared with Start-taper Switch (STS) based on changes in HAMD17 total scores. Overall, that initial data disclosure showed that switch to duloxetine was associated with significant improvements in the emotional symptoms of depression, and was well tolerated and safe, regardless of which SSRI the patient was taking at study entry.

This new analysis focused on the prevalence and severity of painful symptoms following the switch to duloxetine and in relation to switch method. The study participants, as a group, had average pain scores indicating clinically significant physical pain. Ten weeks after switching to duloxetine, patients made significant improvements on all pain measures evaluated, regardless of which switch method was used.¹

Efficacy, safety, and tolerability outcomes following Direct Switch (DS) from SSRI to duloxetine were similar to those observed for Start-taper Switch (STS). The most commonly reported adverse events in the study were headache (13.1 percent for DS vs. 9.7 percent STS), dry mouth (10.4 percent DS vs. 11.9 percent STS), and nausea (8.2 percent DS vs. 8.1 percent STS). No adverse event was reported by significantly more patients in one group compared with the other. An excess of adverse events was not evident following switch from any particular SSRI.¹

“This study provides some much-needed clinical evidence to help physicians successfully switch patients from one antidepressant to another when they remain depressed,” Montejo said. “It also highlights the continued prevalence and severity of painful symptoms among patie
'"/>




Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. In New Study, Duloxetine Reduced Non-specific Pain and Emotional Symptoms Associated with Depression
2. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
3. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
4. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
7. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
8. The International Myeloma Foundation Says New Clinical Trial Results Could Improve Survival While Reducing Side Effects For Many Patients
9. New Study Confirms Role for Pertussis Immunization of Entire Family in Reducing Infant Pertussis
10. Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in Their Phase 2 Clinical Trial
11. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo